Production of recombinant subunit vaccines: Protein immunogens, live delivery systems and nucleic acid vaccines

Journal of Biotechnology

Volumn 73, Issue 1, 1999, Pages 1-33

  Liljeqvist, Sissela ^a   Ståhl, Stefan ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

DNA vaccine; Live bacteria; Protein vaccine; Recombinant; RNA vaccine; Surface display; Vaccine development; Viral vector

Indexed keywords

BACTERIA; BIOLOGY; DISEASES; IMMUNOLOGY; NUCLEIC ACIDS; PATIENT TREATMENT; PRODUCTION ENGINEERING; PROTEINS;

HAEMOPHILUS INFLUENZAE; MOLECULAR BIOLOGY; PROTEIN VACCINE; VACCINATION; VIRAL VECTOR;

VACCINES;

ANTIGEN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HYBRID PROTEIN; LIVE VACCINE; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS VECTOR;

CELL CULTURE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

ANIMALS; GENETIC VECTORS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; IMMUNIZATION, PASSIVE; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RNA; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0345643410     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(99)00107-8     Document Type: Review

References (364)

1. Acheson D.W., Levine M.M., Kaper J.B., Keusch G.T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64:1996;355-357.
2. Acheson D.W.K., Sonenshein A.L., Leong J.M., Keusch G.T. Heat stable spore-based vaccines. Surface expression of invasin-cell wall fusion proteins in Bacillus subtilis. Brown F., Burton D., Doherty P., Mekalanos J., Norrby E. Vaccines 97. 1997;179-184 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
3. Agterberg M., Adriaanse H., Lankhof H., Meloen R., Tommassen J. Outer membrane PhoE protein of Escherichia coli as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus. Vaccine. 8:1990;85-91.
4. Agterberg M., Adriaanse H., van Bruggen A., Karperien M., Tommassen J. Outer-membrane PhoE protein of Escherichia coli K-12 as an exposure vector: possibilities and limitations. Gene. 88:1990;37-45.
5. Alberti E., Acosta A., Sarmiento M.E., Hidalgo C., Vidal T., Fachado A., Fonte L., Izquierdo L., Infante J.F., Finlay C.M., Sierra G. Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library of Trypanosoma cruzi. Vaccine. 16:1998;608-612.
6. Altmeyer R., Escriou N., Girard M., Palmenberg A., van der Werf S. Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120. Proc. Natl. Acad. Sci. USA. 91:1994;9775-9779.
7. Anderson A., Dougan G., Roberts M. Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: expression levels and immune response. Vaccine. 14:1996;1384-1390.
8. Anderson M.J., Porter D.C., Moldoveanu Z., Fletcher T.M.R., McPherson S., Morrow C.D. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res. Hum. Retroviruses. 13:1997;53-62.
9. Andersson C., Sandberg L., Murby M., Sjölander A., Lövgren-Bengtsson K., Ståhl S. General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation. J. Immunol. Methods. 222:1998;171-182.
10. Andréoni C., Goetsch L., Libon C., Samuelson P., Nguyen T.N., Robert A., Uhlén M., Binz H., Ståhl S. Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci. Biotechniques. 23:1997;696-702.
11. Biotechnology medicines and vaccines approved and under development. Genet. Eng. News. 15:12 August, 1995.
12. Arakawa T., Chong D.K.X., Langridge W.H.R. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 16:1998;292-297.
13. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1996;1840-1845.
14. Barry M.A., Johnston S.A. Biological features of genetic immunization. Vaccine. 15:1997;788-791.
15. Barry M.A., Barry M.E., Johnston S.A. Production of monoclonal antibodies by genetic immunization. Biotechniques. 14:1994;616-618.
16. Barry M.A., Lai W.C., Johnston S.A. Protection against mycoplasma infection using expression library immunization. Nature. 377:1995;632-635.
17. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Jr Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70:1996;6418-6424.
18. Ben-Yedidia T., Arnon R. Design of peptide and polypeptide vaccines. Curr. Opin. Biotechnol. 8:1997;442-448.
19. Berglund P., Tubulekas I., Liljeström P. Alphaviruses as vectors for gene delivery. Trends Biotechnol. 14:1996;130-134.
20. Berglund P., Quesada-Rolander M., Putkonen P., Biberfeld G., Thorstensson R., Liljeström P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses. 13:1997;1487-1495.
21. Berglund P., Smerdou C., Fleeton M.N., Tubulekas I., Liljeström P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16:1998;562-565.
22. Billman-Jacobe H. Expression in bacteria other than Escherichia coli. Curr. Opin. Biotechnol. 7:1996;500-504.
23. Bourne N., Milligan G.N., Schleiss M.R., Bernstein D.I., Stanberry L.R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine. 14:1996;1230-1234.
24. Boyer J.D., Ugen K.E., Wang B., Agadjanyan M., Gilbert L., Bagarazzi M.L., Chattergoon M., Frost P., Javadian A., Williams W.V., Refaeli Y., Ciccarelli R.B., McCallus D., Coney L., Weiner D.B. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:1997;526-532.
25. Briand J.-P., Benkirane M., Guichard G., Newman J.F.E., van Regenmortel M.H.V., Brown F., Muller S. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 94:1997;12545-12550.
26. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., Languet B., Chappuis G., Desmettre P. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 354:1991;520-522.
27. Brochier B., Costy F., Pastoret P.P. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet. Microbiol. 46:1995;269-279.
28. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 339:1992;1429-1432.
29. Capon D.J., Chanow S.M., Mordenti J. et al. Designing CD4 immunoadhesins for AIDS therapy. Nature. 337:1989;525-531.
30. Cardoso A.I., Blixenkrone-Moller M., Fayolle J., Liu M., Buckland R., Wild T.F. Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity. Virology. 225:1996;293-299.
31. Carroll M.W., Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8:1997;573-577.
32. Charbit A., Boulain J.C., Ryter A., Hofnung M. Probing the topology of a bacterial membrane protein by genetic insertion of a foreign epitope: expression at the cell surface. EMBO J. 5:1986;3029-3037.
33. Charbit A., Sobczak E., Michel M.-L., Molla A., Tiollais P., Hofnung M. Presentation of two epitopes of the preS2 region of hepatitis B virus on live recombinant bacteria. J. Immunol. 139:1987;1658-1664.
34. Charbit A., Martineau P., Ronco J., Leclerc C., Lo-Man R., Michel V., O'Callaghan D., Hofnung M. Expression and immunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in an attenuated aroA strain of Salmonella typhimurium upon genetic coupling to two Escherichia coli carrier proteins. Vaccine. 11:1993;1221-1227.
35. Chatfield S.N., Charles I.G., Makoff A.J., Oxer M.D., Dougan G., Pickard D., Slater D., Fairweather N.F. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Bio/Technology. 10:1992;888-892.
36. Chatfield S.N., Roberts M., Dougan G., Hormaeche C. The development of oral vaccines against parasitic diseases utilizing live attenuated Salmonella. Parasitology. 110:1995;S17-S24.
37. Chen Z., Wang R.Y.-H., Alter H.J., Shih J.W.-K. Genetic immunization of mice with plasmids containing hepatitis C virus core protein-encoding DNA. Vaccine Res. 4:1995;135-144.
38. Chengalvala M.V., Bhat B.M., Bhat R.A., Dheer S.K., Lubeck M.D., Purcell R.H., Murthy K.K. Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine. 15:1997;335-339.
39. Cheng-hua S., Cheng C., Jing-sheng Z., Jiezhi L., Qing-jun M. Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein. Vaccine. 13:1995;933-937.
40. Chester K.A., Hawkins R.E. Clinical issues in antibody design. Trends Biotechnol. 13:1995;294-300.
41. Chow Y.H., Huang W.L., Chi W.K., Chu Y.D., Tao M.H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:1997;169-178.
42. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
43. Ciernik F., Berzofsky J.A., Carbone D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156:1996;2369-2375.
44. Clackson T., Wells J.A. In vitro selection from protein and peptide libraries. Trends Biotechnol. 12:1994;173-184.
45. Clark M.A., Hirst B.H., Jepson M.A. Inoculum composition and Salmonella pathogenicity Island1 regulate M-cell invasion and epithelial destruction by Salmonella typhimurium. Infect. Immun. 66:1998;724-731.
46. Collins F.M. Salmonellosis in orally infected specific pathogen-free C57BL mice. Infect. Immun. 5:1972;191-198.
47. Conry R.M., LoBuglio A.F., Wright M., Sumerel L., Pike M.J., Johanning F., Benjamin R., Lu D., Curiel D.T. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55:1995;1397-1400.
48. Cornelis P., Cote Sierra J., Lim Jr A., Malur A., Tungpradabkul S., Tazka H., Leitão A., Martins C.V., di Perna C., Brys L., De Baetselier P., Hamers R. Development of new cloning vectors for the production of immunogenic outer membrane fusion proteins in Escherichia coli. Bio/Technology. 14:1996;203-208.
49. c expressing urease A and B subunits. Infect. Immun. 66:1998;581-586.
50. Cowdery J.S., Chace J.H., Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:1996;4570-4575.
51. Cox G.J.M., Zamb T.J., Babiuk L.A. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67:1993;5664-5667.
52. Cox W.I., Tartaglia J., Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology. 195:1993;845-850.
53. Crowe J.E. Jr., Murphy B.R., Chanock R.M., Williamson R.A., Barbas C.F., Burton D.R. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA. 91:1994;1386-1390.
54. Crowe J.E. Jr., Gilmour P.S., Murphy B.R., Chanock R.M., Duan L., Pomerantz R.J., Pilkington G.R. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J. Infect. Dis. 177:1997;1073-1076.
55. Curtiss III R., Kelly S.M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:1987;3035-3043.
56. Curtiss III R., Kelly S.M., Gulig P.A., Nakayama K. Selective delivery of antigens by recombinant bacteria. Curr. Top. Microbiol. Immunol. 146:1989;35-49.
57. Dalgleish A.G., Kennedy R.C. Anti-idiotypic antibodies as immunogens: idiotype-based vaccines. Vaccine. 6:1988;215-220.
58. Dalsgaard K., Uttenthal Å., Jones T.D., Xu F., Merryweather A., Hamilton W.D.O., Langeveld J.P.M., Boshuizen R.S., Kamstrup S., Lomonossoff G.P., Porta C., Vela C., Casal J.I., Meloen R.H., Rodgers P.B. Plant-derived vaccine protects target animals against a viral disease. Nat. Biotechnol. 15:1997;248-252.
59. Darji A., Guzman C.A., Gerstel B., Wachholz P., Timmis K.N., Wehland J., Chakraborty T., Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 91:1997;765-775.
60. Davis H.L. Plasmid DNA expression systems for the purpose of immunization. Curr. Opin. Biotechnol. 8:1997;635-640.
61. Davis H.L., Michel M.L., Whalen R.G. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2:1993;1847-1851.
62. Davis H.L., Mancini M., Michel M.-L., Whalen R.G. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine. 14:1996;910-915.
63. Davis N.L., Brown K.W., Johnston R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:1996;3781-3787.
64. Davis H.L., Weeranta R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
65. de Alboran I., Martinez-alonso C., Barbas 3rd C.F., Burton D.R., Ditzel H.J. Human monoclonal Fab fragments specific for viral antigens from combinatorial IgA libraries. Immunotechnology. 1:1995;21-28.
66. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine. 15:1997;71-78.
67. Deprez B., Sauzet J.-P., Boutillon C., Martinon F., Tartar A., Sergheraert C., Guillet J.-G., Gomard E., Gras-Masse H. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine. 14:1996;375-382.
68. Dertzbaugh M.T., Elson C.O. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 61:1993;48-55.
69. Di Fabio S., Medaglini D., Rush C.M., Corrias F., Panzini G.L., Pace M., Verani P., Pozzi G., Titti F. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine. 16:1998;485-492.
70. Dietrich G., Bubert A., Gentschev I., Sokolovic Z.A.S., Catic A., Kaufmann S.H.E., Hess J., Szalay A.A., Goebel W. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 16:1998;181-185.
71. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., Ulmer J.B., Liu M.A. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1:1995;583-587.
72. Donnelly J.J., Martinez D., Jansen K.U., Ellis R.W., Montgomery D.L., Liu M.A. Protection against papillomaviurs with a polynucleotide vaccine. J. Infect. Dis. 173:1996;314-320.
73. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
74. Doolan D.L., Sedegah M., Hedstrom R.C., Hobart P., Charoenvit Y., Hoffman S.L. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ T cell-, interferon γ-, and nitric oxide-dependent immunity. J. Exp. Med. 183:1996;1739-1746.
75. Dustan S.J., Simmons C.P., Strugnell R.A. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect. Immun. 66:1998;732-740.
76. Echelard Y. Recombinant protein production in transgenic animals. Curr. Opin. Biotechnol. 7:1996;536-540.
77. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J.N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
78. Elliott M.J., Maini R.N., Feldmann M.R.K., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., Woody J.N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
79. Esposito J.J., Knight J.C., Shaddock J.H., Novembre F.J., Baer G.M. Successful oral rabies vaccination of racoons with racoon poxvirus recombinants expressing rabies virus glycoprotein. Virology. 165:1988;313-316.
80. Fairweather N.F., Chatfield S.N., Makoff A.J., Strugnell R.A., Bester J., Maskell D.J., Dougan G. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect. Immun. 58:1990;1323-1326.
81. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunizations. J. Immunol. 158:1997;2278-2284.
82. Fischetti V.A., Hodges W.M., Hruby D.E. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science. 244:1989;1487-1490.
83. Fischetti V.A., Pancholi V., Schneewind O. Conservation of a hexapeptide sequence in the anchor region of surface proteins of Gram-positive cocci. Mol. Microbiol. 4:1990;1603-1605.
84. Fischetti V.A., Medaglini D., Pozzi G. Gram-positive commensal bacteria for mucosal vaccine delivery. Curr. Opin. Biotechnol. 7:1996;659-666.
85. Fooks A.R., Schadeck E., Liebert U.G., Dowsett A.B., Rima B.K., Steward M., Stephenson J.R., Wilkinson G.W. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1- restricted CTL response and protection in a murine model. Virology. 210:1995;456-465.
86. Francisco J.A., Georgiou G. The expression of recombinant proteins on the external surface of Escherichia coli. Ann. New York Acad. Sci. 745:1994;372-382.
87. Francisco J.A., Earhart C.F., Georgiou G. Transport and anchoring of β-lactamase to the external surface of Escherichia coli. Proc. Natl. Acad. Sci. USA. 89:1992;2713-2717.
88. Freudl R. Insertion of peptides into cell-surface-exposed areas of the Escherichia coli OmpA protein does not interfere with export and membrane assembly. Gene. 82:1989;229-236.
89. Freudl R., MacIntyre S., Degen M., Henning U. Cell surface exposure of the outer membrane protein OmpA of Escherichia coli K-12. J. Mol. Biol. 188:1986;491-494.
90. Fu T.M., Ulmer J.B., Caufield M.J., Deck R.R., Friedman A., Wang S., Liu X., Donnelly J.J., Liu M.A. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3:1997;362-371.
91. Fuller D.J., Corb M.M., Barnett S., Steimer K., Haynes J.R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine. 15:1997;924-926.
92. Gaines S., Sprinz H., Tully J.G., Tigertt W.D. Studies on infection and immunity in experimental typhoid fever. VII. The distribution of Salmonella typhi in chimpanzee tissue following oral challenge, and the relationship between the numbers of bacilli and morphologic lesions. J. Infect. Dis. 118:1968;293-306.
93. Galán J.E., Curtiss I.R. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb. Pathog. 6:1989;433-443.
94. Gallichan W.S., Johnson D.C., Graham F.L., Rosenthal K.L. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168:1993;622-629.
95. Geisse S., Gram H., Kleuser B., Kocher H.P. Eukaryotic expression systems: a comparison. Protein Expr. Purif. 8:1996;271-282.
96. Georgiou G., Poetschke H.L., Stathopoulos H., Francisco J.A. Practical applications of engineering Gram-negative bacterial cell surfaces. Trends Biotechnol. 11:1993;6-10.
97. Georgiou G., Stephens D.L., Stathopoulos C., Poetschke H.L., Mendenhall J., Earhart C.F. Display of β-lactamase on the Escherichia coli surface: outer membrane phenotypes conferred by Lpp′-OmpA′-β-lactamase fusions. Protein Eng. 9:1996;239-247.
98. Georgiou G., Strathopoulos C., Daugherty P.S., Nayak A.R., Iverson B.L., Curtiss R.I. Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. 15:1997;29-34.
99. Gerloni M., Ballou W.R., Billetta R., Zanetti M. Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization. Nat. Biotechnol. 15:1997;876-881.
100. Gerloni M., Billetta R., Xiong S., Zanetti M. Somatic transgene immunization with DNA encoding an immunoglobulin heavy chain. DNA Cell Biol. 16:1997;611-625.
101. Germanier R., Furer E. Isolation and characterization of GalE mutant Ty21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:1975;553-558.
102. Gramzinski R.A., Maris D.C., Doolan D., Charoenvit Y., Obaldia N., Rossan R., Sedegah M., Wang R., Hobart P., Margalith M., Hoffman S. Malaria DNA vaccines in Aouts monkeys. Vaccine. 15:1997;913-915.
103. Gräslund T., Nilsson J., Lindberg M., Uhlén M., Nygren P.-Å. Production of a thermostable DNA polymerase by site-specific cleavage of a heat-eluted affinity fusion protein. Protein Expr. Purif. 9:1997;125-132.
104. Gregoriadis G., Saffie R., de Souza J.B. Liposome-mediated DNA vaccination. FEBS Lett. 402:1997;107-110.
105. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R.E., Jones P.T., Low N.M., Allison T.J., Prospero T.D., Hoogenboom H.R., Nissim A., Cox J.P.L., Harrison J.L., Zaccolo M., Gherardi E., Winter G. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
106. Gunneriusson E., Samuelson P., Uhlén M., Nygren P.-Å., Ståhl S. Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol. 178:1996;1341-1346.
107. Guss B., Uhlén M., Nilsson B., Lindberg M., Sjöquist J., Sjödahl J. Region X, the cell wall attachment part of staphylococcal protein A. Eur. J. Biochem. 138:1984;413-420.
108. Hackett J. Use of Salmonella for heterologous gene expression and vaccine delivery systems. Curr. Opin. Biotechnol. 4:1993;611-615.
109. Haddad D., Liljeqvist S., Kumar S., Hansson M., Ståhl S., Perlmann H., Perlmann P., Berzins K. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol. Med. Microbiol. 12:1995;175-186.
110. Haddad D., Liljeqvist S., Ståhl S., Perlmann P., Berzins K., Ahlborg N. Differential induction of immunoglobulin G subclasses by immunization with DNA vectors encoding or lacking a secretion signal. Immunol. Lett. 61:1998;201-204.
111. Hajishengallis G., Hollingshead S.K., Koga T., Russel M.W. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 154:1995;4322-4332.
112. Hannig G., Makrides S.C. Strategies for optimizing heterologous protein expression in Escherichia coli. Trends Biotechnol. 16:1998;54-60.
113. Hansson M., Ståhl S., Nguyen T.N., Bächi T., Robert A., Binz H., Sjölander A., Uhlén M. Expression of recombinant proteins on the surface of the coagulase-negative bacterium Staphylococcus xylosus. J. Bacteriol. 174:1992;4239-4245.
114. Hansson M., Ståhl S., Hjorth R., Uhlén M., Moks T. Single-step recovery of a secreted recombinant protein by expanded bed adsorption. Bio/Technology. 12:1994;285-288.
115. Haq T.A., Mason H.S., Clements J.D., Arntzen C.J. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science. 268:1995;714-716.
116. Harrison J.L., Taylor I.M., O′Connor C.D. Presentation of foreign antigenic determinants at the bacterial cell surface using the TraT lipoprotein. Res. Microbiol. 141:1990;1009-1012.
117. Hawkins R.E., Winger G., Hamblin T.J., Stevenson F.K., Russell S.J. A genetic approach to idiotypic vaccination. J. Immunother. 14:1993;273-278.
118. Hayden M.S., Gilliland L.K., Ledbetter J.A. Antibody engineering. Curr. Opin. Immunol. 9:1997;201-212.
119. He J., Hoffman S.L., Hayes C.G. DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. Vaccine. 15:1997;357-362.
120. Hedegaard L., Klemm P. Type 1 fimbriae of Escherichia coli as carriers of heterologous antigenic sequences. Gene. 85:1989;115-124.
121. Herrmann J.E., Chen S.C., Fynan E.F., Santoro J.C., Greenberg H.B., Wang S., Robinson H.L. Protection against rotavirus infections by DNA vaccination. J. Infect. Dis. 174(Suppl. 1):1996;S93-S97.
122. Hinkula J., Lundholm P., Wahren B. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine. 15:1997;874-878.
123. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak M. Jr., Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
124. Hoiseth S.K., Stocker B.A.D. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 291:1981;238-239.
125. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A.-M. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am. J. Trop. Med. Hyg. 50:1994;42-54.
126. Hone D.M., Harris A.M., Chatfield S., Dougan G., Levine M.M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 9:1991;810-816.
127. Hoogenboom H.R. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15:1997;62-70.
128. Hopkins S.A., Kraehenbuhl J.-P. Dendritic cells of the murine Peyer′s patches colocalize with Salmonella typhimurium avirulent mutants in the subepithelial dome. Ricciardi-Castagnoli P. Dendritic Cells in Fundamental and Clinical Immunology. 1997;105-109 Plenum Press, New York.
129. Hopkins S., Kraehenbuhl J.-P., Schödel F., Potts A., Peterson D., De Grandi P., Nardelli-Haefliger D. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:1995;3279-3286.
130. Hsu C.H., Chua K.Y., Tao M.H., Lai Y.L., Wu H.D., Huang S.K., Hsieh K.H. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat. Med. 2:1996;540-544.
131. Hsu S.-C., Schadeck E.B., Delmas A., Shaw M., Steward M.W. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. Vaccine. 14:1996;1159-1166.
132. Hu L., Esposito J.J., Scott F.W. Raccoon poxvirus feline panleukopenia virus VP2 recombinant protects cats against FPV challenge. Virology. 218:1996;248-252.
133. Huang L., Li S. Liposomal gene delivery: a complex package. Nat. Biotechnol. 15:1997;620-621.
134. Hurle M.R., Gross M. Protein engineering techniques for antibody humanization. Curr. Opin. Biotechnol. 5:1994;428-433.
135. Huygen K., Content J., Montgomery D.L., Yawman A.M., Deck R.R., DeWitt C.M., Orme I.M., Baldwin S., D′Souza C., Drowart A., Lozes E., Vandenbussche P., Van Vooren J.-P., Liu M.A., Ulmer J.B. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 8:1996;893-898.
136. Iacono-Connors L.C., Welkos S.L., Ivins B.E., Dalrymple J.M. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1991;1961-1965.
137. Ichikawa Y., Yamagata H., Tochikubo K., Udaka S. Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis. FEMS Microbiol. Lett. 111:1993;219-224.
138. Imler J.L. Adenovirus vectors as recombinant viral vaccines. Vaccine. 13:1995;1143-1151.
139. Iwaki M., Okahashi N., Takahashi I., Kanamoto T., Sugita-Konishi Y., Aibara K., Koga T. Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect. Immun. 28:1990;2929-2934.
140. Jacobsson, K., 1997. Shotgun phage display. Ph.D. thesis, Swedish University of Agricultural Sciences.
141. Jacobsson K., Frykberg L. Cloning of ligand-binding domains of bacterial receptors by phage display. Biotechniques. 18:1995;878-885.
142. Jacobsson K., Frykberg L. Gene VIII-based, phage-display vectors for selection against complex mixtures of ligands. Biotechniques. 24:1998;294-301.
143. Janssen R., Wauben M., van der Zee R., Tommassen J. Immunogenicity of a mycobacterial T-cell epitope expressed in outer membrane protein PhoE of Escherichia coli. Vaccine. 12:1994;406-409.
144. Johanning F.W., Conry R.M., LoBuglio A.F., Wright M., Sumerel L.A., Pike M.J., Curiel D.T. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res. 23:1995;1495-1501.
145. Johnson K., Charles I., Dougan G., Pickard D., O'Gaora P., Costa G., Ali T., Miller I., Hormaeche C. The role of a stress-response protein in Salmonella typhimurium virulence. Mol. Microbiol. 5:1991;401-407.
146. Johnston S.A., Barry M.A. Genetic to genomic vaccination. Vaccine. 15:1997;808-810.
147. Jonasson P., Nygren P.-Å., Johansson B.-L., Wahren J., Uhlén M., Ståhl S. Gene fragment polymerization gives increased yields of recombinant human proinsulin C-peptide. Gene. 210:1998;203-210.
148. Karem K.L., Bowen J., Kuklin N., Rouse B.T. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J. Gen. Virol. 78:1997;427-434.
149. Katz E., Moss B. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. AIDS Res. Hum. Retroviruses. 13:1997;1497-1500.
150. Katz E., Wolffe E.J., Moss B. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J. Virol. 71:1997;3178-3187.
151. Khan C.M., Villarreal-Ramos B., Pierce R.J., Riveau G., Demarco de Hormaeche R., McNeill H., Ali T., Fariweather N., Chatfield S., Capron A. et al. Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA. 91:1994;11261-11265.
152. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M.A., Dang K., Wang B., Boyer J.D., Weiner D.B. In vivo engineering of a cellular immune response by coadministraion of IL-12 expression vector with a DNA immunogen. J. Immunol. 158:1997;816-826.
153. Kim J.J., Bagarazzi M.L., Trivedi N., Hu Y., Kazahaya K., Wilson D.M., Ciccarelli R., Chattergoon M.A., Dang K., Mahalingam S., Chalian A.A., Agadjanyan M.G., Boyer J.D., Wang B., Weiner D.B. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Biotechnol. 15:1997;641-646.
154. Kjerrulf M., Löwenadler B., Svanholm C., Lycke N. Tandem repeats of T helper epitopes enhance immunogenicity of fusion proteins by promoting processing and presentation. Mol. Immunol. 34:1997;599-608.
155. Klauser T., Pohlner J., Meyer T.F. Extracellular transport of cholera toxin B subunit using Neisseria IgA protease β-domain: conformation-dependent outer membrane location. EMBO J. 9:1990;1991-1999.
156. Klauser T., Pohlner J., Meyer T.F. Selective extracellular release of cholera toxin B subunit by Escherichia coli: dissection of Neisseria Igaβ-mediated outer membrane transport. EMBO J. 11:1992;2327-2335.
157. Klee S.R., Tzschaschel B.D., Timmis K.N., Guzman C.A. Influence of different rol gene products on the chain length of Shigella dysenteriae type 1 lipopolysaccharide O antigen expressed by Shigella flexneri carrier strain. J. Bacteriol. 179:1997;2421-2425.
158. Klein T.M., Fitzpatrick-McElligott S. Particle bombardment: a universal approach for gene transfer to cells and tissues. Curr. Opin. Biotechnol. 4:1993;582-590.
159. Klinman D.M., Yamshchikov G., Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158:1997;3635-3639.
160. Kornacker M.G., Pugsley A.P. The normally periplasmic enzyme β-lactamase is specifically and efficiently translocated through the Escherichia coli outer membrane when it is fused to the cell-surface enzyme pullulanase. Mol. Microbiol. 4:1990;1101-1109.
161. Koths K. Recombinant proteins for medical use: the attractions and challenges. Curr. Opin. Biotechnol. 6:1995;681-687.
162. Krasemann S., Groschup M., Hunsmann G., Bodemer W. Induction of antibodies against human prion proteins (PrP) by DNA-mediated immunization of PrP0/0 mice. J. Immunol. Methods. 199:1996;109-118.
163. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
164. b mice. J. Immunol. 156:1996;3687-3695.
165. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 71:1997;3138-3145.
166. Kuwajima G., Asaka J.-I., Fujiwara T., Nakano K., Kondoh E. Presentation of an antigenic determinant from hen egg-white lysozyme on the flagellar filament of Escherichia coli. Bio/Technology. 6:1988;1080-1083.
167. Lång H., Korhonen T.K. The OmpS maltoporin of Vibrio cholerae as carrier of foreign epitopes. Behring Inst. Mitt. 98:1997;400-409.
168. LaVallie E.R., McCoy J.M. Gene fusion expression systems in Escherichia coli. Curr. Opin. Biotechnol. 6:1995;501-506.
169. Lebens M., Shahabi V., Bäckström M., Houze T., Lindblad M., Holmgren J. Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine. Infect. Immun. 64:1996;2144-2150.
170. Leclerc C., Martineau P., van der Werf S., Deriaud E., Duplay P., Hofnung M. Induction of virus-neutralizing antibodies by bacteria expressing the C3 poliovirus epitope in the periplasm. The route of immunization influences the isotypic distribution and the biologic activity of the antipoliovirus antibodies. J. Immunol. 144:1990;3174-3182.
171. Leclerc C., Charbit A., Martineau P., Deriaud E., Hofnung M. The cellular location of a foreign B cell epitope expressed by recombinant bacteria determines its T cell-independent or T cell-dependent characteristics. J. Immunol. 147:1991;3545-3552.
172. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., Alroy M., Freed D.C., Lord C.I., Handt L.K., Liu M.A., Shiver J.W. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA. 94:1997;9378-9383.
173. Levine M.M., Hone D., Tacket C., Ferreccio C., Cryz S. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as 'carrier' vaccines. Res. Microbiol. 141:1990;807-816.
174. Lewis J.G., Lin K.Y., Kothavale A., Flanagan W.M., Matteucci M.D., DePrince R.B., Mook R.A.J., Hendren R.W., Wagner R.W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA. 93:1996;3176-3181.
175. Libon C., Corvaïa N., Haeuw J.-F., Nguyen T.N., Ståhl S., Bonnefoy J.-F., Andréoni C. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. Vaccine. 17:1999;406-414.
176. Liljeqvist S., Haddad D., Berzins K., Uhlén M., Ståhl S. A novel expression system for Salmonella typhimurium allowing high production levels, product secretion and efficient recovery. Biochem. Biophys. Res. Commun. 218:1996;356-359.
177. Liljeqvist S., Samuelson P., Hansson M., Nguyen T.N., Binz H., Ståhl S. Surface display of the cholera toxin B subunit on Staphylococcus xylosus and Staphylococcus carnosus. Appl. Environ. Microbiol. 63:1997;2481-2488.
178. Liljeqvist S., Ståhl S., Andréoni C., Binz H., Uhlén M., Murby M. Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. J. Immunol. Methods. 210:1997;125-136.
179. Löwenadler B., Lycke N. Fusion proteins with heterologous T helper epitopes. Recombinant E. coli heat-stable enterotoxin proteins. Int. Rev. Immunol. 11:1994;103-111.
180. Lu S., Manson K., Wyland M., Robinson H.L. SIV DNA vaccine trial in macaques: post-challenge necropsy in vaccine and control groups. Vaccine. 15:1997;920-923.
181. Lubeck M.D., Davis A.R., Chengalvala M., Natuk R.J., Morin J.E., Molnar-Kimber K., Mason B.B., Bhat B.M., Mizutani S., Hung P.P. et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. USA. 86:1989;6763-6767.
182. Luke C.J., Carner K., Liang X., Barbour A.G. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J. Infect. Dis. 175:1997;91-97.
183. Ma J.K., Smith R., Lehner T. Use of monoclonal antibodies in local passive immunization to prevent colonization of human teeth by Streptococcus mutans. Infect. Immun. 55:1987;1274-1278.
184. Ma J.K., Hunjan M., Smith R., Kelly C., Lehner T. An investigation into the mechanism of protection by local passive immunization with monoclonal antibodies against Streptococcus mutans. Infect. Immun. 58:1990;3407-3414.
185. Ma J.K., Hiatt A., Hein M., Vine N.D., Wang F., Stabila P., van Dolleweerd C., Mostov K., Tehner T. Generation and assembly of secretory antibodies in plants. Science. 268:1995;716-719.
186. Mackett M., Smith G.L., Moss B. A selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA. 79:1982;7415-7419.
187. Major M.E., Vitvitski L., Mink M.A., Schleef M., Whalen R.G., Trepo C., Inchauspe G. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69:1995;5798-5805.
188. Makrides S.C. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev. 60:1996;512-538.
189. Makrides S.C., Nygren P.-Å., Andrews B., Ford P.J., Evans K.S., Hayman E.G., Adari H., Levin J., Uhlén M., Tothe C.A. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J. Pharmacol. Exp. Ther. 277:1996;534-542.
190. Malmborg A.C., Duenas M., Ohlin M., Söderlind E., Borrebaeck C.A. Selection of binders from phage displayed antibody libraries using the BIAcore biosensor. J. Immunol. Methods. 198:1996;51-57.
191. Mancini M., Hadchouel M., Davis H.L., Whalen R.G., Tiollais P., Michel M.L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl. Acad. Sci. USA. 93:1996;12496-12501.
192. Manickan E., Yu Z., Rouse R.J., Wire W.S., Rouse B.T. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. Viral Immunol. 8:1995;53-61.
193. Martin-Gallardo A., Fleischer E., Doyle S.A., Arumugham R., Collins P.L., Hildreth S.W., Paradiso P.R. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 74:1993;453-458.
194. Martinon F., Krishnana S., Lenzen G., Magne R., Gomard E., Guillet J.G., Levy J.P., Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23:1993;1719-1722.
195. Martins L.P., Lau L.L., Asano M.S., Ahmed R. DNA vaccination against persistent viral infection. J. Virol. 69:1995;2574-2582.
196. Mason H.S., Arntzen C.J. Transgenic plants as vaccine production systems. Trends Biotechnol. 13:1995;388-392.
197. Mason H.S., Lam D.M., Arntzen C.J. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA. 89:1992;11745-11749.
198. Mason H.S., Ball J.M., Shi J.J., Jiang X., Estes M.K., Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA. 93:1996;5335-5340.
199. Maurer J., Jose J., Meyer T.F. Autodisplay: one-component system for efficient surface display and release of soluble recombinant proteins from Escherichia coli. J. Bacteriol. 179:1997;794-804.
200. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 348:1990;552-554.
201. McCarroll L., King L.A. Stable insect cell cultures for recombinant protein production. Curr. Opin. Biotechnol. 8:1997;590-594.
202. McEwen J., Levi R., Horwitz R.J., Arnon R. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine. 10:1992;405-411.
203. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 10:1992;75-88.
204. McMahon-Pratt D., Rodriguez D., Rodriguez J.R., Zhang Y., Manson K., Bergman C., Rivas L., Rodriguez J.F., Lohman K.L., Ruddle N.H., Esteban M. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 61:1993;3351-3359.
205. Medaglini D., Pozzi G., King T.P., Fischetti V.A. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl. Acad. Sci. USA. 92:1995;6868-6872.
206. Medaglini D., Rush C.M., Sestini P., Pozzi G. Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine. 15:1997;1330-1337.
207. Mézière C., Viguier M., Dumortier H., Lo-Man R., Leclerc C., Guillet J.-G., Briand J.-P., Muller S. In vivo T helper cell response to retro-inverso peptidomimetics. J. Immunol. 159:1997;3230-3237.
208. Michel M.-L., Davis H.L., Schleef M., Mancini M., Tiollais P., Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infections in humans. Proc. Natl. Acad. Sci. USA. 92:1995;5307-5311.
209. Mielcarek N., Riveau G., Remoué F., Antoine R., Capron A., Locht C. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16:1998;454-457.
210. Mittal S.K., Papp Z., Tikoo S.K., Baca-Estrada M.E., Yoo D., Benko M., Babiuk L.A. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology. 222:1996;299-309.
211. + responses in mice. Proc. Natl. Acad. Sci. USA. 95:1998;3954-3959.
212. Moks T., Abrahmsén L., Österlöf B., Josephson S., Östling M., Enfors S.-O., Persson I., Nilsson B., Uhlén M. Large-scale affinity purification of human insulin-like growth factor I from culture medium of Escherichia coli. Bio/Technology. 5:1987;379-382.
213. Mor G., Klinman D.M., Shapiro S., Hagiwara E., Sedegah M., Norman J.A., Hoffman S.L., Steinberg A.D. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J. Immunol. 155:1995;2039-2046.
214. Moss B., Smith G.L., Gerin J.L., Purcell R.H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 311:1984;67-69.
215. Mossman S.P., Bex F., Berglund P., Arthos J., O'Neil S.P., Riley D., Maul D.H., Bruck C., Momin P., Burny A., Fultz P.N., Mullins J.I., Liljeström P., Hoover E.A. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70:1996;1953-1960.
216. Murby M., Nguyen T.N., Binz H., Uhlén M., Ståhl S. Production and recovery of recombinant proteins of low solubility. Pyle D.L. Separations for Biotechnology 3. 1994;336-344 Bookcraft Ltd, Bath, UK.
217. Murby M., Samuelsson E., Nguyen T.N., Mignard L., Power U., Binz H., Uhlen M., Ståhl S. Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 230:1995;38-44.
218. Murby M., Uhlen M., Ståhl S. Upstream strategies to minimize proteolytic degradation upon recombinant production in Escherichia coli. Protein Expr. Purif. 7:1996;129-136.
219. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., Grassauer A., Engelhardt O.G., Garcia-Sastre A., Palese P., Katinger H. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69:1995;6678-6686.
220. Myagkikh M., Alipanah S., Markham P.D., Tartaglia J., Paoletti E., Gallo R.C., Franchini G., Robert-Guroff M. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses. 12:1996;985-992.
221. Nagahama M., Michiue K., Sakurai J. Production and purification of Clostridium perfringens alpha-toxin using a protein-hyperproducing strain, Bacillus brevis 47. FEMS Microbiol. Lett. 145:1996;239-243.
222. Nardelli-Haefliger D., Kraehenbuhl J.-P., Curtiss III R., Schödel F., Potts A., Kelly S., De Grandi P. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect. Immun. 64:1996;5219-5224.
223. Nardelli-Haefliger D., Roden R.B.S., Benyacoub J., Sahli R., Kraehenbuhl J.-P., Schiller J.T., Lachat P., Potts A., De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. 65:1997;3328-3336.
224. Navarre W.W., Schneewind O. Proteolytic cleavage and cell wall anchoring at the LPXTG motif of surface proteins in Gram-positive bacteria. Mol. Microbiol. 14:1994;115-121.
225. Newton S.M.C., Jacob C.O., Stocker B.A.D. Immune response to cholera toxin epitope inserted in Salmonella flagellin. Science. 244:1989;70-72.
226. Nguyen T.N., Hansson M., Ståhl S., Bächi T., Robert A., Domzig W., Binz H., Uhlén M. Cell-surface display of heterologous epitopes on Staphylococcus xylosus as a potential delivery system for oral vaccination. Gene. 128:1993;89-94.
227. Nguyen T.N., Gourdon M.-H., Hansson M., Robert A., Samuelson P., Libon C., Andréoni C., Nygren P.-Å., Binz H., Uhlén M., Ståhl S. Hydrophobicity engineering to facilitate surface display of heterologous gene products on Staphylococcus xylosus. J. Biotechnol. 42:1995;207-219.
228. Nilsson J., Ståhl S., Lundeberg J., Uhlén M., Nygren P.-Å. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr. Purif. 11:1997;1-16.
229. Norton P.M., Brown H.W.G., Wells J.M., Macpherson A.M., Wilson P.W., Le Page R.W.F. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis. FEMS Immunol. Med. Microbiol. 14:1996;167-177.
230. Norton P.M., Wells J.M., Brown H.W.G., Macpherson A.M., Le Page R.W.F. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine. 15:1997;616-619.
231. Nygren P.-Å., Uhlén M. Scaffolds for engineering novel binding sites in proteins. Curr. Opin. Struct. Biol. 7:1997;463-469.
232. Nygren P.-Å., Eliasson M., Palmcrantz E., Abrahmsén L., Uhlén M. Analysis and use of the serum albumin binding domains of streptococcal protein G. J. Mol. Recognit. 1:1988;69-74.
233. Nygren P.-Å., Flodby P., Andersson R., Wigzell H., Uhlén M. In vivo stabilization of a human recombinant CD4 derivative by fusion to a serum albumin-binding receptor. Chanock R.M. et al. Vaccines 91, Modern Approaches to Vaccine Development. 1991;363-368 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
234. Nygren P.-Å., Ståhl S., Uhlén M. Engineering proteins to facilitate bioprocessing. Trends Biotechnol. 12:1994;184-188.
235. O'Callaghan D., Maskell D., Liew R.Y., Easmon C.S.F., Dougan G. Characterization of aromatic- and purine-dependent Salmonella typhimurium: attenuation, persistence, and ability to induce protective immunity in BALB/c mice. Infect. Immun. 56:1988;419-423.
236. O'Donnell M.A. The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotechnol. 15:1997;512-517.
237. Ogawa R., Yanagida N., Saeki S., Saito S., Ohkawa S., Gotoh H., Kodama K., Kamogawa K., Sawaguchi K., Iritani Y. Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses. Vaccine. 8:1990;486-490.
238. Oggioni M.R., Manganelli R., Contorni M., Tommasino M., Pozzi G. Immunization of mice by oral colonization with live recombinant commensal streptococci. Vaccine. 13:1995;775-779.
239. Ohno K., Sawai K., Iijima Y., Levin B., Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat. Biotechnol. 15:1997;763-767.
240. Owens R.J., Young R.J. The genetic engineering of monoclonal antibodies. J. Immunol. Methods. 168:1994;149-165.
241. Pallesen L., Poulsen L.K., Christiansen G., Klemm P. Chimeric FimH adhesin of type 1 fimbriae: a bacterial surface display system for heterologous sequences. Microbiology. 141:1995;2839-2848.
242. Pande H., Campo K., Tanamachi B., Forman S.J., Zaia J.A. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand. J. Infect. Dis. Suppl. 99:1995;117-120.
243. Panicali D., Paoletti E. Construction of poxviurses as cloning vectors: insertion of the TK gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA. 79:1982;4927-4931.
244. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA. 93:1996;11349-11353.
245. Pardoll D.M., Beckerleg A.M. Exposing the immunology of naked DNA vaccines. Immunity. 3:1995;165-169.
246. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L.A., Ponton G. et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature. 332:1988;158-161.
247. Perkus M.E., Tartaglia J., Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukocyte Biol. 58:1995;1-13.
248. Pertmer R.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol. 70:1996;6119-6125.
249. Phillpotts R.J., Venugopal K., Brooks T. Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. Arch. Virol. 141:1996;743-749.
250. Piard J.C., Hautefort I., Fischetti V.A., Erlich S.D., Fons M., Gruss A. Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J. Bacteriol. 179:1997;3068-3072.
251. Plotkin S.A. Vaccination in the 21st century. J. Infect. Dis. 168:1993;29-37.
252. Plückthun A. Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol. Rev. 130:1992;151-188.
253. Pohlner J., Halter R., Beyreuther K., Meyer T.F. Gene structure and extracellular secretion of Neisseria gonorrhoeae IgA protease. Nature. 325:1987;458-462.
254. Possee R.D. Baculoviruses as expression vectors. Curr. Opin. Biotechnol. 8:1997;569-572.
255. Power U.F., Plotnicky-Gilquin H., Huss T., Robert A., Trudel M., Ståhl S., Uhlén M., Nguyen T.N., Binz H. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 230:1997;155-166.
256. Pozza T., Yan H., Meek D., Guzmán C.A., Walker M.J. Construction and characterization of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits. Vaccine. 16:1998;522-529.
257. Pozzi G., Contorni M., Oggioni M.R., Manganelli R., Tommasino M., Cavalieri P., Fischetti V.A. Delivery and expression of a heterologous antigen on the surface of Streptococci. Infect. Immun. 60:1992;1902-1907.
258. Pozzi G., Oggioni M.R., Manganelli R., Medaglini D., Fischetti V.A., Fenoglio D., Valle M.T., Kunkl A., Manca F. Human T-helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. Vaccine. 12:1994;1071-1077.
259. Pugachev K.V., Mason P.W., Shope R.E., Frey T.K. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology. 212:1995;587-594.
260. Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine. 15:1997;892-895.
261. Raz E., Tighe H., Sato Y., Corr M., Dudler J.A., Roman M., Swain S.L., Spiegelberg H.L., Carson D.A. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA. 93:1996;5141-5145.
262. Restifo N.P. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8:1996;658-663.
263. Ridder R., Schmitz R., Legay F., Gram H. Generation of rabbit monoclonal antibody fragments from a combinatorial phage display library and their production in the yeast Pichia pastoris. Bio/Technology. 13:1995;255-260.
264. Robbins P.D., Tahara H., Ghivizzani S.C. Viral vectors for gene therapy. Trends Biotechnol. 16:1998;35-40.
265. Robert A., Samuelson P., Andréoni C., Bächi T., Uhlén M., Binz H., Nguyen T.N., Ståhl S. Surface display on staphylococci: a comparative study. FEBS Lett. 390:1996;327-333.
266. Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., LePage R.W.F. Oral vaccination of mice against tetanus with recombinant Lacotcoccus lactis. Nat. Biotechnol. 15:1997;653-657.
267. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.-D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854.
268. Romero C.H., Barrett R., Chamberlain R.W., Kitching R.P., Fleming M., Black D.N. Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses. Virology. 204:1994;425-429.
269. Ruppert A., Arnold N., Hobom G. OmpA-FMDV VP1 fusion proteins: production, cell surface exposure and immune responses to the major antigenic domain of foot-and-mouth disease virus. Vaccine. 12:1994;492-498.
270. Rush C.M., Mercenier A., Pozzi G. Expression of vaccine antigens in Lactobacillus. Pozzi G., Wells J.M. Gram-Positive Bacteria as Vaccine Vehicles for Mucosal Immunization. 1997;107-144 R.G. Landes Biomedical, New York.
271. Rüssmann H., Shams H., Poblete F., Fu Y., Galán J.E., Donis R.O. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science. 281:1998;565-568.
272. Ryd V., Verma N., Lindberg A.A. Induction of a humoral immune response to a Shiga toxin B subunit epitope expressed as a chimeric LamB protein in a Shigella flexneri live vaccine strain. Microbiol. Pathog. 12:1992;399-407.
273. Sadoff J.C., Ballou W.R., Baron L.S., Majarian W.R., Brey R.N., Hockmeyer W.T., Young J.F., Cryx S.J., Ou J., Lowell G.H., Chulay J.D. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 240:1988;336-338.
274. Samuelson P., Hansson M., Ahlborg N., Andréoni C., Götz F., Bächi T., Nguyen T.N., Binz H., Uhlén M., Ståhl S. Cell surface display of recombinant proteins on Staphylococcus carnosus. J. Bacteriol. 177:1995;1470-1476.
275. Samuelsson E., Wadensten H., Hartmanis M., Moks T., Uhlén M. Facilitated in vitro refolding of human recombinant insulin-like growth factor I using a solubilizing fusion partner. Bio/Technology. 9:1991;363-366.
276. Samuelsson E., Moks T., Nilsson B., Uhlén M. Enhanced in vitro refolding of insulin-like growth factor I using a solubilizing fusion partner. Biochemistry. 33:1994;4207-4211.
277. Sandhu J.S., Keating A., Hozumi N. Human gene therapy. Crit. Rev. Biotechnol. 17:1997;307-326.
278. Saron M.F., Fayolle C., Sebo P., Ladant D., Ullmann A., Leclerc C. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA. 94:1997;3314-3319.
279. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.-D., Silverman G.J., Lotz M., Carson D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
280. d mice that reject syngeneic tumors. J. Immunol. 157:1996;3550-3558.
281. Schneewind O., Model P., Fischetti V.A. Sorting of protein A to the staphylococcal cell wall. Cell. 70:1992;267-281.
282. Schneewind O., Mihaylova-Petkov D., Model P. Cell wall sorting signals in surface proteins of Gram-positive bacteria. EMBO J. 12:1993;4803-4811.
283. Schneewind O., Fowler A., Faull K.F. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Nature. 268:1995;103-106.
284. Schödel F., Millich D.R., Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J. Immunol. 145:1990;4317-4321.
285. Schödel F., Will H., Johansson S., Sanchez J., Holmgren J. Synthesis in Vibrio cholerae and secretion of hepatitis B virus antigens fused to Escherichia coli heat-labile enterotoxin subunit B. Gene. 99:1991;255-259.
286. Schorr J., Knapp B., Hundt E., Kupper H., Amann E. Surface expression of malarial antigens in E. coli and Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccines. 91:1991;387-392.
287. Schorr J., Knapp B., Hundt E., Kupper H.A., Amann E. Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine. 9:1991;675-681.
288. Schreuder M.P., Mooren A.T., Toschka H.Y., Verrips C.T., Klis F.M. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol. 14:1996;115-120.
289. Schrijver R.S., Langedijk P.M., Keil G.M., Middel W.G.J., Maris-Veldhuis M., Van Oirschot J.T., Rijsewijk F.A.M. Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV. Vaccine. 15:1997;1908-1916.
290. Schubbert R., Renz D., Schmitz B., Doerfler W. Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liver via the intestinal wall mucosa and can be covalently linked to mouse DNA. Proc. Natl. Acad. Sci. USA. 94:1997;961-966.
291. Sedegah M., Hedstrom R., Hobart P., Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. USA. 91:1994;9866-9870.
292. Sedlik C., Saron M.-F., Sarraseca J., Casal I., Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 94:1997;7503-7508.
293. Simard C., Nadon F., Séguin C., Nguyen T.N., Binz H., Basso J., Laliberté J.-F., Trudel M. Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: the role of cysteinyl residues in protection. Vaccine. 15:1997;423-432.
294. Sizemore D.R., Branstrom A.A., Sadoff J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science. 270:1995;299-302.
295. Sizemore D.R., Branstrom A.A., Sadoff J.C. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine. 15:1997;804-807.
296. Sjölander A., Ståhl S., Perlmann P. Bacterial expression systems based on protein A and protein G designed for the production of immunogens: applications to Plasmodium falciparum malaria antigens. Immunomethods. 2:1993;79-92.
297. Sjölander A., Nygren P.-Å., Ståhl S., Berzins K., Uhlén M., Perlmann P., Andersson R. The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties. J. Immunol. Methods. 201:1997;115-123.
298. Smerdou C., Anton I.M., Plana J., Curtiss R.I., Enjuanes L. A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity. Virus Res. 41:1996;1-9.
299. Smith G.L., Murphy B.R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc. Natl. Acad. Sci. USA. 80:1983;7155-7159.
300. Sory M.P., Hermand P., Vaerman J.P., Cornelis G.R. Oral immunization of mice with a live recombinant Yersinia enterocolitica O:9 strain that produces the cholera toxin B subunit. Infect. Immun. 58:1990;2420-2428.
301. Staats H.F., Jackson R.J., Marinaro M., Takahashi I., Kiyono H., McGhee J.R. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. 6:1994;572-583.
302. Ståhl S., Uhlén M. Bacterial surface display: trends and progress. Trends Biotechnol. 15:1997;185-192.
303. Ståhl S., Samuelson P., Hansson M., Andréoni C., Goetsch L., Libon C., Liljeqvist S., Gunneriusson E., Binz H., Nguyen T.N., Uhlén M. Development of non-pathogenic staphylococci as vaccine delivery vehicles. Wells J., Pozzi G. Recombinant Gram-Positive Bacteria as Vaccine Vehicles for Mucosal Immunization. 1997;61-81 R.G. Landes Biomedical, New York.
304. Steidler L., Remaut E., Fiers W. Pap pili as a vector system for surface exposition of an immunoglobulin G-binding domain of protein A of Staphylococcus aureus in Escherichia coli. J. Bacteriol. 175:1993;7639-7643.
305. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.A., Bennett L.T., Bansal G.P., Young J.F., Lee M.H., Hatfull G.F., Snapper S.B., Barletta R.G., Jacobs W.R., Bloom B.R. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.
306. Stover C.K., Bansal G.P., Hanson M.S., Burlein J.E., Palaszynski S.R., Young M.S., Koenig S., Young D.B., Sadziene A., Barbour A.G. Protective immunity elicited by recombinant Bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate lyme disease vaccine. J. Exp. Med. 178:1993;197-209.
307. Strauss A., Götz F. In vivo immobilization of enzymatically active polypeptides on the cell surface of Staphylococcus carnosus. Mol. Microbiol. 21:1996;491-500.
308. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:1994;491-562.
309. Su G.-F., Brahmbhatt H.N., Wehland J., Rohde M., Timmis K.N. Construction of stable LamB-shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses. Infect. Immun. 60:1992;3345-3359.
310. Suarez A., Staender L.H., Rohde M., Piatti G., Timmis K.H., Guzmán C.A. Stable expression of pertussis toxin in Bordetella bronchiseptica under the control of a tightly regulated promoter. Appl. Environ. Microbiol. 63:1997;122-127.
311. Sudbery P.E. The expression of recombinant proteins in yeasts. Curr. Opin. Biotechnol. 7:1996;517-524.
312. Sultan F., Jun L.-L., Jobling M.G., Holmes R.K., Stanley Jr S.L. Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infect. Immun. 66:1998;462-468.
313. Sun J.-B., Holmgren J., Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA. 91:1994;10795-10799.
314. Sutter G., Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 89:1992;10847-10851.
315. Tacket C.O., Hone D.M., Curtiss III R., Kelly S.M., Losonsky G., Guers L., Harris A.M., Edelman R., Levine M.M. Comparison of the safety and immunogenicity of Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:1992;536-541.
316. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Nataro J.P., Edelman R., Pickard D., Dougan G., Chatfield S.N., Levine M.M. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:1997;452-456.
317. Tacket C.O., Mason H.S., Losonsky G., Clements J.D., Levine M.M., Arntzen C.J. Immunogenicity in humans of a recombinant bacterial antigen delivered in a
318. Tam J.P. Recent advances in multiple antigen peptides. J. Immunol. Methods. 196:1996;17-32.
319. Tang D.-C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
320. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., Davis S.W., van der Hoeven J., Meignier B., Rivière M., Languet B., Paoletti E. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 188:1992;217-232.
321. Tascon R.E., Colston M.J., Ragno S., Stavropoulos E., Gregory D., Lowrie D.B. Vaccination against tuberculosis by DNA injection. Nat. Med. 8:1996;888-892.
322. Thanavala Y., Yang Y.F., Lyons P., Mason H.S., Arntzen C. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA. 92:1995;3358-3361.
323. Tine J.A., Lanar D.E., Smith D.M., Wellde B.T., Schultheiss P., Ware L.A., Kauffman E.B., Wirtz R.A., Detaisne C., Hui G., Chang S.P., Church P., Kaslow D.C., Hoffman S., Guito K.P., Ballou W.R., Sadoff J.C., Paoletti E. NYVAC-Pf7 - a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64:1996;3833-3844.
324. Ton-That H., Faull K.F., Schneewind O. Anchor structure of staphylococcal surface proteins. J. Biol. Chem. 272:1997;22285-22292.
325. Torres C.A.T., Iwasaki A., Barber B.H., Robinson H.L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158:1997;4529-4532.
326. Trill J.J., Shatzman A.R., Ganguly S. Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 6:1995;553-560.
327. Tubulekas I., Berglund P., Fleeton M., Liljeström P. Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene. 190:1997;191-195.
328. Tzschaschel B.D., Guzmán C.A., Timmis K.N., de Lorenzo V. An Escherichia coli hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin IIeB subunit by Salmonella typhimurium aroA. Nat. Biotechnol. 14:1996;765-769.
329. Uhlén M., Forsberg G., Moks T., Hartmanis M., Nilsson B. Fusion proteins in biotechnology. Curr. Opin. Biotechnol. 3:1992;363-369.
330. Ulaeto D., Hruby D.E. Uses of vaccinia virus in vaccine delivery. Curr. Opin. Biotechnol. 5:1994;501-504.
331. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.A., Martinez D., Perry H.C., Shiver J.W., Montgomery D.L., Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
332. Ulmer J.B., Deck R.R., Dewitt C.M., Donnelly J.J., Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology. 89:1996;59-67.
333. Ulmer J.B., Donnelly J.J., Liu M.A. Toward the development of DNA vaccines. Curr. Opin. Biotechnol. 7:1996;653-658.
334. Ulmer J.B., Sadoff J.C., Liu M.A. DNA vaccines. Curr. Opin. Immunol. 8:1996;531-536.
335. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 298:1982;347-350.
336. Van Die I., Wauben M., Van Megen I., Bergmans H., Riegman N., Hoekstra W., Pouwels P., Enger-Valk B. Genetic manipulation of major P-fimbrial subunits and consequences for formation of fimbriae. J. Bacteriol. 170:1988;5870-5876.
337. Viret J.F., Cryz S.J.J., Favre D. Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae. Mol. Microbiol. 19:1996;949-963.
338. Waine G.J., Yang W., Scott J.C., McManus D.P., Kalinna B.H. DNA-based vaccination using Schistosoma japonicum (Asian blood-fluke). Vaccine. 15:1997;846-848.
339. Waisman A., Ruiz P.J., Hirschberg D.L., Gelman A., Oksenberg J.R., Brocke S., Mor F., Cohen I.R., Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. 8:1996;899-905.
340. Walker M.J., Rohde M., Timmis K.N., Guzman C.A. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Infect. Immun. 60:1992;4260-4268.
341. Wang B., Ugen K.E., Srikantan V., Agadjanyan M.G., Dang K., Refaeli Y., Boyer J., Williams W.V., Weiner D.B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 90:1993;4156-4160.
342. Weickert M.J., Doherty D.H., Best E.A., Olins P.O. Optimization of heterologous protein production in Escherichia coli. Curr. Opin. Biotechnol. 7:1996;494-499.
343. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94:1997;10833-10837.
344. Wells J.M., Wilson P.W., Norton P.M., Gasson M.J., Le Page R.W.F. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8:1993;1155-1162.
345. Wells J.M., Wilson P.W., Norton P.M., Le Page R.W.F. A model system for the investigation of heterologous protein secretion pathways in Lactococcus lactis. Appl. Environm. Microbiol. 59:1993;3954-3959.
346. Wick M.J., Pfeifer J.D., Findlay K.A., Harding C.V., Normark S.J. Compartmentalization of defined epitopes expressed in Escherichia coli has only a minor influence of efficiency of phagocytic processing for presentation by class I and class II major histocompatability complex molecules to T cells. Infect. Immun. 61:1993;4848-4856.
347. Winter G., Milstein C. Man-made antibodies. Nature. 349:1991;293-299.
348. Wolff J.A., Malone R.W., Williams P., Chong W., Ascadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
349. Wu J.Y., Newton S., Judd A., Stocker B., Robinson W.S. Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA. 86:1989;4726-4730.
350. Xiang Z., Ertl H.C.J. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 2:1995;129-135.
351. Xiang Z.Q., Spitalnik S., Tran M., Wunner W.H., Cheng J., Ertl H.C. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 199:1994;132-140.
352. Xiang Z.Q., Yang Y., Wilson J.M., Ertl H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 219:1996;220-227.
353. Xiong S., Gerloni M., Zanetti M. Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes. Nat. Biotechnol. 15:1997;882-886.
354. Xiong S., Gerloni M., Zanetti M. In vivo role of B lymphocytes in somatic transgene immunization. Proc. Natl. Acad. Sci. USA. 94:1997;6352-6357.
355. Xu D., Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology. 84:1995;173-176.
356. Xu L., Sanchez A., Yang Z.-Y., Zaki S.R., Nabel E.G., Nichol S.T., Nabel G.J. Immunization for Ebola virus infection. Nat. Med. 4:1998;37-42.
357. Yang W., Waine G.J., McManus D.P. Antibodies to Schistosoma japonicum (Asian bloodfluke) paramyosin induced by nucleic acid vaccination. Biochem. Biophys. Res. Commun. 212:1995;1029-1039.
358. Yankauckas M.A., Morrow J.E., Parker S.E., Abai A., Rhodes G.H., Dwarki V.J., Grmkowski S.H. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol. 12:1993;771-776.
359. Yim T.J., Tang S., Andino R. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. Virology. 218:1996;61-70.
360. Yokoyama M., Zhang J., Whitton J.L. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J. Virol. 69:1995;2684-2688.
361. Zanetti M. Antigenized antibodies. Nature. 355:1992;476-477.
362. Zhang T., Li E., Stanley J.S.L. Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. Infect. Immun. 63:1995;1349-1355.
363. Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., Liljeström P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 12:1994;1510-1514.
364. Zhou X., Berglund P., Zhao H., Liljeström P., Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA. 92:1995;3009-3013.